We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pre-Markets Flat Ahead of JOLTS; Q4 Earnings for PFE, PYPL, PEP & More
Read MoreHide Full Article
Tuesday, February 4, 2025
We are flat with a downward bias a half-hour before the market opens this Tuesday, with more earnings results reporting favorable conditions in Q4 but potential resistance in Q1. The Dow is -89 points at this hour, the S&P 500 is exactly 0 and the Nasdaq is +28 points. The small-cap Russell 2000 is down -1 point.
After today’s open, we’ll get the first labor market report of the week (which culminates in the big non-farm payroll Employment Situation report Friday morning) with the Job Openings and Labor Turnover Survey (JOLTS). This data will report for December, whereas the rest of the jobs reports, also including private-sector payrolls from ADP (ADP - Free Report) tomorrow ahead of the bell, reflect January tallies.
Also, Factory Orders for December come out shortly after regular trading starts today. Expectations are for -0.8% for the month, doubling the previous month’s -0.4% and equaling the lowest print since August of last year. Should goods-producing efforts within our shores manifest in the future, we may see a turnaround here — though we wouldn’t expect this in the near-term.
Q4 Earnings Reports Today: PFE, MRK, PYPL & More
Pfizer (PFE - Free Report) put up its most impressive quarterly numbers in recent memory today, beating estimates on the bottom line by more than +30%: 63 cents per share versus 48 cents expected. Revenues of $17.76 billion surpassed the Zacks consensus by +1.52%, on Covid vaccination sales that outperformed expectations. Guidance was in-line with earlier projections. Shares of PFE had been down slightly year to date, and are up +0.6% on its earnings news. For more on PFE’s earnings, click here.
Merck (MRK - Free Report) also outpaced estimates in its Q4 report this morning, albeit not quite as impressively: earnings of $1.72 per share beat the Zacks consensus by 3 cents, while $15.62 billion in quarterly sales bettered estimates by +0.45%. Yet guidance was lowered on disappointing sales of its HPV vaccine Gardasil, and Merck shares are down -8.4% in today’s pre-market. For more on MRK’s earnings, click here.
PayPal (PYPL - Free Report) — otherwise known as where Elon Musk made his first billion dollars — outperformed expectations this morning on both top and bottom lines in its Q4 report. Earnings of $1.19 per share were a couple steps ahead of the $1.13 estimate, while revenues of $8.37 billion in the quarter were +1.67% ahead of where analysts were anticipating. Yet higher guidance was not enough to overcome the miss on Branded Payment Volume Growth, and shares are -8% ahead of the opening bell. For more on PYPL’s earnings, click here.
PepsiCo (PEP - Free Report) beat by a penny to $1.96 per share — nicely ahead of the $1.78 per share reported in the year-ago quarter — on $27.78 billion in quarterly sales which barely missed expectations by -0.4%. North American demand slipped in the quarter, and shares are -2.5% in pre-market trading at this hour. For more on PEP’s earnings, click here.
Image: Bigstock
Pre-Markets Flat Ahead of JOLTS; Q4 Earnings for PFE, PYPL, PEP & More
Tuesday, February 4, 2025
We are flat with a downward bias a half-hour before the market opens this Tuesday, with more earnings results reporting favorable conditions in Q4 but potential resistance in Q1. The Dow is -89 points at this hour, the S&P 500 is exactly 0 and the Nasdaq is +28 points. The small-cap Russell 2000 is down -1 point.
After today’s open, we’ll get the first labor market report of the week (which culminates in the big non-farm payroll Employment Situation report Friday morning) with the Job Openings and Labor Turnover Survey (JOLTS). This data will report for December, whereas the rest of the jobs reports, also including private-sector payrolls from ADP (ADP - Free Report) tomorrow ahead of the bell, reflect January tallies.
Also, Factory Orders for December come out shortly after regular trading starts today. Expectations are for -0.8% for the month, doubling the previous month’s -0.4% and equaling the lowest print since August of last year. Should goods-producing efforts within our shores manifest in the future, we may see a turnaround here — though we wouldn’t expect this in the near-term.
Q4 Earnings Reports Today: PFE, MRK, PYPL & More
Pfizer (PFE - Free Report) put up its most impressive quarterly numbers in recent memory today, beating estimates on the bottom line by more than +30%: 63 cents per share versus 48 cents expected. Revenues of $17.76 billion surpassed the Zacks consensus by +1.52%, on Covid vaccination sales that outperformed expectations. Guidance was in-line with earlier projections. Shares of PFE had been down slightly year to date, and are up +0.6% on its earnings news. For more on PFE’s earnings, click here.
Check out the updated Zacks Earnings Calendar here.
Merck (MRK - Free Report) also outpaced estimates in its Q4 report this morning, albeit not quite as impressively: earnings of $1.72 per share beat the Zacks consensus by 3 cents, while $15.62 billion in quarterly sales bettered estimates by +0.45%. Yet guidance was lowered on disappointing sales of its HPV vaccine Gardasil, and Merck shares are down -8.4% in today’s pre-market. For more on MRK’s earnings, click here.
PayPal (PYPL - Free Report) — otherwise known as where Elon Musk made his first billion dollars — outperformed expectations this morning on both top and bottom lines in its Q4 report. Earnings of $1.19 per share were a couple steps ahead of the $1.13 estimate, while revenues of $8.37 billion in the quarter were +1.67% ahead of where analysts were anticipating. Yet higher guidance was not enough to overcome the miss on Branded Payment Volume Growth, and shares are -8% ahead of the opening bell. For more on PYPL’s earnings, click here.
PepsiCo (PEP - Free Report) beat by a penny to $1.96 per share — nicely ahead of the $1.78 per share reported in the year-ago quarter — on $27.78 billion in quarterly sales which barely missed expectations by -0.4%. North American demand slipped in the quarter, and shares are -2.5% in pre-market trading at this hour. For more on PEP’s earnings, click here.
Questions or comments about this article and/or author? Click here>>